Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib

Current Topics in Medicinal Chemistry

Volumn 12, Issue 15, 2012, Pages 1649-1659

  Erdem, Lale ^a   Giovannetti, Elisa ^a   Leon, Leticia G ^a   Honeywell, Richard ^a   Peters, Godefridus J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Erlotinib; Gefitinib; Outcome; Polymorphisms; Sorafenib; Sunitinib; Toxicity; Tyrosine kinase inhibitors

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CARBOPLATIN; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; GLUCURONOSYLTRANSFERASE 1A1; MAMMALIAN TARGET OF RAPAMYCIN; PEMETREXED; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB;

ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CANCER PROGNOSIS; CHROMOSOME 14; CHROMOSOME 4; CHROMOSOME 7; DIARRHEA; DRUG ACTIVITY; DRUG MECHANISM; DRUG TOLERABILITY; EXON; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENOTYPE; GERM LINE; HAND FOOT SYNDROME; HEAD AND NECK CANCER; HUMAN; INTRON; KIDNEY CANCER; KIDNEY CARCINOMA; LEUKOPENIA; LIQUID CHROMATOGRAPHY; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PATIENT SELECTION; PHARMACOGENETICS; PREDICTION; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RASH; SKIN TOXICITY; SOLID TUMOR; STOMATITIS; STUDY DESIGN; TANDEM MASS SPECTROMETRY; THYROID CANCER; VALIDATION STUDY;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CLINICAL TRIALS AS TOPIC; GERM-LINE MUTATION; HUMANS; INDOLES; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRROLES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84867570442     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/156802612803531333     Document Type: Article

References (66)

1. Baselga, J. Targeting tyrosine kinases in cancer: the second wave. Science, 2006; 312, 1175-1178.
2. Hoang, T.; Schiller, J.H. Advanced NSCLC: from cytotoxic systemic chemotherapy to molecularly targeted therapy. Expert. Rev. Anticancer. Ther., 2002, 2, 393-401.
3. Manning G, Whyte D.B, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science, 2002, 298, 1912-1934.
4. Weinberg, R.A.; Cytoplasmic signaling circuitry programs many of the traits of cancer. In: The biology of cancer; Eds: Garland Science, 2006, Chapter 6, pp.159-208.
5. Hynes, N.E.; Lane, H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer., 2005, 5, 341-354.
6. Zhang, J.; Yang, P.L.; Gray, N.S. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer., 2009, 9, 28-39.
7. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer, 2007, 7,169-81.
8. Marsh, S.; Mallon, M.A.; Goodfellow, P.; McLeod, H.L. Concordance of pharmacogenetic markers in germline and colorectal tumour DNA. Pharmacogenomics, 2005, 6, 873-877.
9. Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell. 2000,103, 211-225.
10. Jorissen, R.N.; Walker, F.; Pouliot, N.; Garrett, T.P.J.; Ward, C.W.; Burgess A.W. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp. Cell. Res., 2003, 284, 31-53.
11. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur. J. Cancer, 37, 9-15 (2001)
12. Scaltriti, M.; Baselga, J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin. Cancer. Res.,2006, 12, 5268-5272.
13. Scagliotti, G.V.; Selvaggi, G.; Novello, S.; Hirsch, F.R. The biology of epidermal growth factor receptor in lung cancer. Clin. Cancer. Res.,2004, 10, 4227s-4232s.
14. Kim, E.S.; Hirsh, V.; Mok, T; Socinski M.A.; Gervais, R.; Wu, Y.L.; Li, L.Y.; Watkins, C.L.; Sellers, M.V.; Lowe, E.S.; Sun, Y.; Liao, M.L.; Osterlind, K.; Reck, M.; Armour, A.A.; Shepherd, F.A.; Lippman, S.M.; Douillard, J.Y. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet, 2008, 372, 1809-1818.
15. Shepherd, F.A.; Rodrigues, P.J.; Ciuleanu, T.; Tan, E.H.; Hirsh, V.; Thongprasert, S.; Campos, D.; Maoleekoonpiroj, S.; Smylie, M.; Martins, R.; van Kooten, M.; Dediu, M.; Findlay, B.; Tu, D.; Johnston, D.; Bezjak, A.; Clark, G.; Santabárbara, P.; Seymour, L.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med., 2005, 353, 123-132.
16. Sanford, M.; Scott, L.J. Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer. Drugs, 2009, 69, 2303-2328.
17. Helfrich, B.A.; Raben, D.; Varella-Garcia, M, Gustafson, D.; Chan, D.C.; Bemis, L.; Coldren, C.; Barón, A.; Zeng, C.; Franklin, W.A.; Hirsch, F.R.; Gazdar, A.; Minna, J.; Bunn, P.A. Jr. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin. Cancer. Res., 2006, 12, 7117-7125.
18. Hartmann, J.T.; Haap, M.; Kopp, H.G.; Lipp, H.P. Tyrosine kinase inhibitors a review on pharmacology, metabolism and side effects. Curr Drug Metab., 2009, 10, 470-481.
19. Liu, W.; Innocenti, F.; Wu, M.H.; Desai A.A.; Dolan, M.E.; Cook, E.H.; Ratain, M.J., Jr A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res., 2005, 65, 46-53.
20. Nomura, M.; Shigematsu, H.; Li, L.; Suzuki, M.; Takahashi, T.; Estess, P.; Siegelman, M.; Feng, Z.; Kato, H.; Marchetti, A.; Shay, J.W.; Spitz, M.R.; Wistuba, I.I.; Minna J.D.; Gazdar, A.F. Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Med., 2007, 4, e125.
21. Moriai, T.; Kobrin, M.S.; Hope, C.; Speck, L.; Korc, M. A variant epidermal growth factor receptor exhibits altered type a transforming growth factor binding and transmembrane signaling. Proc. Natl. Acad. Sci. USA, 1994, 91, 10217-10221.
22. Gebhardt, F.; Bürger, H.; Brandt, B. Modulation of EGFR gene transcription by secondary structures, a polymorphic repetitive sequence and mutations--a link between genetics and epigenetics. Histol. Histopathol. 2000, 15, 929-936.
23. Gebhardt, F.; Zänker, K.S.; Brandt, B. Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J. Biol. Chem. 1999, 274, 13176-13180.
24. Buerger, H.; Gebhardt, F.; Schmidt, H.; Beckmann, A.; Hutmacher, K.; Simon, R.; Lelle, R.; Boecker, W.; Brandt, B. Length and loss of heterozygosity of an intron 1 polymorphic sequence of egfr is related to cytogenetic alterations and epithelial growth factor receptor expression. Cancer Res., 2000, 60, 854-857.
25. Ichihara, S.; Toyooka, S.; Fujiwara, Y.; Hotta, K.; Shigematsu, H.; Tokumo, M.; Soh, J.; Asano, H.; Ichimura, K.; Aoe, K.; Aoe, M.; Kiura, K.; Shimizu, K.; Date, H. The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small cell lung cancer. Int. J. Cancer, 2007, 120, 1239-1247.
26. Han, S.W.; Jeon, Y.K.; Lee, K.H.; Keam, B.; Hwang, P.G.; Oh, D.Y.; Lee, S.H.; Kim, D.W.; Im, S.A.; Chung, D.H.; Heo, D.S.; Bang, Y.J.; Kim, T.Y. Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small cell lung cancer. Pharmacogenet. Genomics, 2007, 17, 313-319.
27. Nie, Q.; Wang, Z.; Zhang, G.C.; An, S.J.; Lin, J.Y.; Guo, A.L.; Li, R.; Gan, B.; Huang, Y.; Mok, T.S.; Wu, Y.L. The epidermal growth factor receptor intron 1 (CA)n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with gefitinib. Eur. J. Pharmacol., 2007, 570, 175-181.
28. Liu, G.; Gurubhagavatula, S.; Zhou, W.; Wang, Z.; Yeap, B.Y.; Asomaning, K.; Su, L.; Heist, R.; Lynch, T.J.; Christiani, D.C. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small cell lung cancer patients treated with gefitinib. Pharmacogenomics J., 2008, 8(2), 129-138.
29. Tiseo, M.; Capelletti, M.; De Palma, G.; Franciosi, V.; Cavazzoni, A.; Mozzoni, P.; Alfieri, R.R.; Goldoni, M.; Galetti, M.; Bortesi, B.; Bozzetti, C.; Loprevite, M.; Boni L,; Camisa, R.; Rindi, G.; Petronini, P.G.; Ardizzoni, A. Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer. J Thorac Oncol., 2008, 3(10),1104-1111.
30. Tiseo, M.; Rossi, G.; Capelletti, M.; Sartori, G.; Spiritelli, E.; Marchioni, A.; Bozzetti, C.; De Palma G, Lagrasta C, Campanini N, Camisa R, Boni L, Franciosi V, Rindi G, Ardizzoni A. Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers. Lung Cancer. 2010, 67, 355-360.
31. Gregorc, V.; Hidalgo, M.; Spreafico, A.; Cusatis, G.; Ludovini, V.; Ingersoll, R.G.; Marsh, S.; Steinberg, S.M.; Viganò, M.G.; Ghio, D.; Villa, E.; Sparreboom, A.; Baker, S.D. Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib. Clin. Pharmacol. Ther., 2008, 83(3), 477-484.
32. Giovannetti, E.; Zucali, P.A.; Peters, G.J.; Cortesi, F.; D'Incecco, A.; Smit, E.F.; Falcone, A.; Burgers, J.A.; Santoro, A.; Danesi, R.; Giaccone, G.; Tibaldi, C. Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib. Mol. Cancer Ther., 2010, 9(3), 581-593.
33. Ma, F.; Sun, T.; Shi, Y.; Yu, D.; Tan, W.; Yang, M.; Wu, C.; Chu, D.; Sun, Y.; Xu, B.; Lin, D. Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib. Lung Cancer, 2009, 66(1), 114-119.
34. Perez-Soler, R.; Saltz, L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J. Clin. Oncol., 2005, 23, 5235-5246.
35. Huang, C.L.; Yang, C.H.; Yeh, K.H.; Hu, F.C.; Chen, K.Y.; Shih, J.Y.; Lin, Z.Z.; Yu, C.J.; Cheng, A.L.; Yang, P.C. EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment. Lung Cancer, 2009, 64(3), 346-351.
36. Dubey, S.; Stephenson, P.; Levy, D.E.; Miller, J.A.; Keller, S.M.; Schiller, J.H.; Johnson, D.H.; Kolesar, J.M.; Eastern Cooperative Oncology Group. EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer. J. Thorac. Oncol., 2006, 1, 406-412.
37. Tzeng, C.W.; Frolov, A.; Frolova, N.; Jhala, N.C.; Howard, J.H.; Vickers, S.M.; Buchsbaum, D.J.; Heslin, M.J.; Arnoletti, J.P. Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response. Ann. Surg. Oncol., 2007, 14(7), 2150-2158.
38. Frolov, A.; Liles, J.S.; Kossenkov, A.V.; Tzeng, C.W.; Jhala, N.; Kulesza, P.; Varadarajulu, S.; Eloubeidi, M.; Heslin, M.J.; Arnoletti, J.P. Epidermal growth factor receptor (EGFR) intron 1 polymorphism and clinical outcome in pancreatic adenocarcinoma. Am. J. Surg., 2010, Apr 19. [Epub ahead of print]
39. Sasaki, H.; Okuda, K.; Shimizu, S.; Takada, M.; Kawahara, M.; Kitahara, N.; Okumura, M.; Matsumura, A.; Iuchi, K.; Kawaguchi, T.; Kubo, A.; Kawano, O.; Yukiue, H.; Yano, M.; Fujii, Y. EGFR R497K polymorphism is a favorable prognostic factor for advanced lung cancer. J. Cancer Res. Clin. Oncol., 2009, 135(2), 313-318.
40. Cappuzzo, F.; Magrini, E.; Ceresoli, G.L.; Bartolini, S.; Rossi, E.; Ludovini, V.; Gregorc, V.; Ligorio, C.; Cancellieri, A.; Damiani, S.; Spreafico, A.; Paties, C.T.; Lombardo, L.; Calandri, C.; Bellezza, G.; Tonato, M.; Crinò, L. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J. Natl. Cancer. Inst,. 2004, 96, 1133-1141.
41. Cappuzzo, F.; Ligorio, C.; Jänne, P.A.; Toschi, L.; Rossi, E.; Trisolini, R.; Paioli, D.; Holmes, A.J.; Magrini, E.; Finocchiaro, G.; Bartolini, S.; Cancellieri, A.; Ciardiello, F.; Patelli, M.; Crino, L.; Varella-Garcia, M. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridizationpositive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J. Clin. Oncol., 2007, 25, 2248-2255.
42. Kim, M.S.; Jeong, E.G.; Yoo, N.J.; Lee, S.H. Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. Br. J. Cancer, 2008, 98, 1533-1535.
43. Harris, S.L.; Gil, G.; Robins, H.; Hu, W.; Hirshfield, K.; Bond, E.; Bond, G.; Levine, A.J. Detection of functional single-nucleotide polymorphisms that affect apoptosis. Proc. Natl. Acad. Sci. USA, 2005, 102, 16297-16302.
44. Emamian, E.S.; Hall Birnbaum, M.J.; Karayiorgou, M.; Gogos, J.A. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat. Genet., 2004, 36, 131-137.
45. Hildebrandt, M.A.; Yang, H.; Hung, M.C.; Izzo, J.G.; Huang, M.; Lin, J.; Ajani, J.A.; Wu, X. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical out-come in esophageal cancer patients treated with chemotherapy. J. Clin. Oncol., 2009, 27, 857-871.
46. Lemos, C.; Jansen, G.; Peters, G.J. Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors. Br. J. Cancer, 2008, 98, 857-862.
47. Li, J.; Cusatis, G.; Brahmer, J.; Sparreboom, A.; Robey, R.W.; Bates, S.E.; Hidalgo, M.; Baker, S.D. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. Cancer Biol. Ther., 2007, 6, 432-438.
48. Cusatis, G.; Gregorc, V.; Li, J.; Spreafico, A.; Ingersoll, R.G.; Verweij, J.; Ludovini, V.; Villa, E.; Hidalgo, M.; Sparreboom, A.; Baker, S.D. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J. Natl. Cancer Inst., 2006, 98, 1739-1742.
49. Lemos, C.; Giovannetti, E.; Zucali, P.A.; Assaraf, Y.G.; Scheffer, G.L.; van der Straaten, T.; D'Incecco, A; Falcone, A.; Guchelaar, H.J.; Danesi, R.; Santoro, A.; Giaccone, G.; Tibaldi, C.; Peters, G.J. Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients. Pharmacogenomics., 2011, 12, 159-170.
50. Liu, W.; Wu, X.; Zhang, W.; Montenegro, R.C.; Fackenthal, D.L.; Spitz, J.A.; Huff, L.M.; Innocenti, F.; Das, S.; Cook, E.H.Jr.; Cox, N.J.; Bates, S.E.; Ratain, M.J. Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. Clin. Cancer. Res., 2007, 15, 13(22 Pt 1), 6788-6795.
51. Amador, M.L.; Oppenheimer, D.; Perea, S.; Maitra, A.; Cusatis, G.; Iacobuzio-Donahue, C.; Baker, S.D.; Ashfaq, R.; Takimoto, C.; Forastiere, A.; Hidalgo, M. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res., 2004, 15, 64(24), 9139-9143.
52. Rudin, C.M.; Liu, W.; Desai, A.; Karrison, T.; Jiang, X.; Janisch, L; Das, S.; Ramirez, J.; Poonkuzhali, B.; Schuetz, E.; Fackenthal, D.L.; Chen, P.; Armstrong, D.K.; Brahmer, J.R.; Fleming, G.F.; Vokes, E.E; Carducci, M.A.; Ratain, M.J. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J. Clin. Oncol., 2008, 26, 1119-1127.
53. Rodriguez-Antona, C.; Ingelman-Sundberg, M. Cytochrome P450 pharmacogenetics and cancer. Oncogene, 2006, 13, 25(11), 1679-1691.
54. Li, J.; Zhao, M.; He, P.; Hidalgo, M.; Baker, S.D. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin. Cancer. Res., 2007, 15, 13(12), 3731-3737.
55. Wilhelm, S.M.; Carter, C.; Tang, L.; Wilkie, D.; McNabola, A.; Rong, H, Chen, C.; Zhang, X.; Vincent, P.; McHugh, M.; Cao, Y.; Shujath, J.; Gawlak, S.; Eveleigh, D.; Rowley, B.; Liu, L.; Adnane, L.; Lynch, M.; Auclair, D.; Taylor, I.; Gedrich, R.; Voznesensky, A.; Riedl, B.; Post, L.E.; Bollag, G.; Trail, P.A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res., 2004, 1, 64(19), 7099-7109.
56. Gatzemeier, U.; Blumenschein, G.; Fosella, F.; Simantov, R.; Elting, J.; Bigwood, D. Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. J. Clin. Oncol., (Meeting Abstracts) 2006 Jun 20;24(18_suppl):7002.
57. Lind, J.S.; Dingemans, A.M.; Groen, H.J.; Thunnissen, E.; Bekers, O.; Heideman, D.A.; Honeywell, R.; Giovannetti, E.; Peters, G.J.; Postmus, P.E.; van Suylen, R.J.; Smit, E.F. Clin. Cancer Res., 2010, 16, 3078-3087.
58. Meza-Junco, J.; Chu, Q.S.C.; Christensen, O.; Rajagopalan, P.; Das, S.; Stefanyschyn, R.; Sawyer, M.B. UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib. Cancer. Chemother. Pharmacol., 2009, 65, 1-4.
59. Iyer, L.; King, C.D.; Whitington, P.F.; Green, M.D.; Roy, S.K.; Tephly, T.R.; Coffman, B.L.; Ratain, M.J. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J. Clin. Invest., 1998, 15, 101(4), 847-854.
60. Beutler, E.; Gelbart, T.; Demina, A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc. Natl. Acad. Sci. U S A, 1998, 7, 95(14), 8170-8174.
61. Monaghan, G.; Ryan, M.; Seddon, R.; Hume, R.; Burchell, B. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet, 1996, 2, 347(9001), 578-581.
62. van Erp, N.P.; Gelderblom, H.; Guchelaar, H.J. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat. Rev., 2009, 35(8), 692-706.
63. van Erp, N.P.; Eechoute, K.; van der Veldt, A.A.; Haanen, J.B.; Reyners, A.K.; Mathijssen, R.H.; Boven, E.; van der Straaten, T.; Baak-Pablo, R.F.; Wessels, J.A.; Guchelaar, H.J.; Gelderblom, H. Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J. Clin. Oncol., 2009, 10, 27(26), 4406-4412.
64. Mizuno, T.; Terada, T.; Kamba, T.; Fukudo, M.; Katsura, T.; Nakamura, E.; Ogawa, O.; Inui, K. ABCG2 421CA polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma. Ann. Oncol., 2010, 21, 1382-1383.
65. Honeywell, R.; Yarzadah, K.; Giovannetti, E.; Losekoot, N.; Smit, E.F.; Walraven, M.; Lind, J.S.; Tibaldi, C.; Verheul, H.M.; Peters, G.J. Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 2010, 1, 878(15-16), 1059-1068.
66. Giovannetti E, Erdem L, Olcay E, Leon LG, Peters GJ. Influence of polymorphisms on EGFR targeted therapy in non-small cell lung cancer. Front. Biosciences 2010, 16, 116-130.